Search Result

Results for "

CDK2 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (91) AAK1 (2) Akt (2) AMPK (2) Anaplastic lymphoma kinase (ALK) (3) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (19) Aurora Kinase (2) Autophagy (2) Bcl-2 Family (4) c-Kit (1) c-Myc (1) Carbonic Anhydrase (1) Casein Kinase (1) Caspase (3) CFTR (1) Checkpoint Kinase (Chk) (2) COX (1) CXCR (3) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (1) EGFR (7) Ephrin Receptor (1) ERK (1) FAK (2) FGFR (2) FLT3 (1) GSK-3 (11) IAP (1) IKK (1) IRAK (1) Isotope-Labeled Compounds (1) Itk (1) JAK (2) JNK (3) Ligands for Target Protein for PROTAC (1) LIM Kinase (LIMK) (1) MAP4K (1) MDM-2/p53 (1) MEK (2) MELK (1) Microtubule/Tubulin (1) Molecular Glues (1) mTOR (1) Necroptosis (1) P-glycoprotein (2) p38 MAPK (1) Parasite (1) PARP (1) PI3K (3) Pim (4) PKA (1) PKC (8) PKD (2) PROTACs (5) Reference Standards (8) Salt-inducible Kinase (SIK) (1) Ser/Thr Kinase (2) SGK (1) SnRK (1) Src (4) Trk Receptor (2) ULK (1) VEGFR (8) Wee1 (3)
By Research Areas:	Cancer (94) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (16) Metabolic Disease (2) Neurological Disease (14)
Click Chemistry:	Alkynes (1)

105

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10329

JNJ-7706621 5 Publications Verification	Aurora Kinase CDK Apoptosis	Cancer
JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits *CDK1* and *CDK2, with IC₅₀s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A* and aurora-B, respectively .

HY-101212

Fadraciclib 5+ Cited Publications CYC065	CDK	Cancer
Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of *CDK2/CDK9* kinases with IC₅₀s of 5 and 26 nM, respectively .

HY-114177

Ebvaciclib 4 Publications Verification PF-06873600	CDK	Cancer
PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase *(CDK), with K_i* values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .

HY-175749

BMS-986463	Molecular Glues Wee1	Inflammation/Immunology Cancer
BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader. BMS-986463 significantly inhibits tumor regression and reduces the level of phospho-CDK2. BMS-986463 can be used for advanced malignant solid tumors like non-small cell lung cancer (NSCLC) research .

HY-158106

AZD8421 1 Publications Verification	CDK	Cancer
AZD8421 is a selective *CDK2* inhibitor (IC₅₀ = 9 nM) as well as achieving CDK family selectivity in cells versus key off-targets (CDK1, CDK4/6, CDK9), AZD8421 had no significant kinase inhibition outside the CDK family. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest in G1/S phase and senescence. AZD8421 can be studied in research for breast cancer and ovarian cancer .

HY-122609

XO44 PF-6808472	CDK	Cancer
XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. XO44 can bind in *CDK2 and CDK1. XO44 also labels CDK4* proteins in cells .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of *CDK* and *Tropomyosin receptor kinase* (TRK), with IC₅₀*s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK*1 and TRKA, respectively.

HY-13914

Roniciclib 2 Publications Verification BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase *(CDK)* inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-15532

SCH900776 10+ Cited Publications MK-8776	Checkpoint Kinase (Chk)	Cancer
SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC₅₀ of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively .

HY-12214A

NVP-2 Maximum Cited Publications 41 Publications Verification	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include *CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin* A (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-18981

Decursin 2 Publications Verification (+)-Decursin	PKC Apoptosis CXCR	Neurological Disease Inflammation/Immunology Cancer
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent *protein kinase* C activator. Decursin induces apoptosis** and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-11001

PHA-793887 4 Publications Verification	CDK Apoptosis	Cancer
PHA-793887 is a potent, ATP-competitive *CDK* inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC₅₀s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC₅₀ of 79 nM.

HY-15275

BMS-265246 2 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase *CDK1* and *CDK2* inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-N5072

Desmethylglycitein 3 Publications Verification 4',6,7-Trihydroxyisoflavone	CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to *CDK1* and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-13941

1-Naphthyl PP1 3 Publications Verification 1-NA-PP 1	Src PKD	Neurological Disease Inflammation/Immunology Cancer
1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of src family kinases and *Protein Kinase* D*. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2* and CAMK II with IC₅₀s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases *CDK1, CDK2, and CDK4* with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-11010

AS601245 5+ Cited Publications	JNK	Neurological Disease Inflammation/Immunology Cancer
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a *CDK* inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and *p35-CDK5* with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-148065

FMF-06-098-1	PROTACs Wee1 CDK AAK1 ULK MELK Itk IRAK Ephrin Receptor FGFR MAP4K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .

HY-W011428

Olomoucine 1 Publications Verification	CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of *CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin* A, Cdk2/cyclin E (both IC₅₀=7 μM), CDK/p35 kinase (IC₅₀=3 μM) and ERK1/p44 MAP kinase (IC₅₀=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-103647

K00546	CDK VEGFR GSK-3	Cancer
K00546 is a potent *CDK1* and *CDK2* inhibitor with IC₅₀s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent *CDC2-like kinase* 1 (CLK1) and CLK3 inhibitor with IC₅₀**s of 8.9 nM and 29.2 nM, respectively .

HY-112358

GW8510	CDK	Neurological Disease Cancer
GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .

HY-18299

Purvalanol B 2 Publications Verification NG 95	CDK Parasite	Infection Cancer
Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor *CDK, with IC₅₀s of 6 nM, 6 nM, 9 nM, 6 nM for cdc2-cyclin B, CDK2-cyclin* A, CDK2-cyclin E and *CDK5-p35, respectively. Purvalanol B shows selectivity for CDK* over a range of other protein kinases (IC₅₀>1000 nM). Purvalanol B inhibits the growth a chloroquine-resistant strain of P. falciparum .

HY-13941B

1-Naphthyl PP1 hydrochloride 3 Publications Verification 1-NA-PP 1 hydrochloride	Src PKD	Neurological Disease Inflammation/Immunology Cancer
1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases and *Protein Kinase* D*. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2* and CAMK II with IC₅₀s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .

HY-124760

hSMG-1 inhibitor 11e 3 Publications Verification	mTOR PI3K CDK	Cancer
hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC₅₀ of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC₅₀ of 45 nM), PI3Kα/γ (IC₅₀s of 61 nM and 92 nM) and CDK1/CDK2 (IC₅₀s of 32 μM and 7.1 μM) .

HY-108136A

Bisindolylmaleimide X hydrochloride 2 Publications Verification BIM-X hydrochloride; Ro31-8425 hydrochloride	PKC CDK	Cardiovascular Disease Inflammation/Immunology Cancer
Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC₅₀ of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .

HY-112626

CDK12-IN-2 1 Publications Verification	CDK	Cancer
CDK12-IN-2 is a potent, selective and nanomolar *CDK12* inhibitor (IC₅₀=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .

HY-159805

CDK2-IN-31	CDK	Cancer
CDK2-IN-31 is a *CCNE1:CDK2* complex inhibitor with an IC₅₀ of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer .

HY-108348

BML-259	CDK	Neurological Disease
BML-259 is a potent cyclin-dependent kinase 5 *(Cdk5)* inhibitor, with IC₅₀s of 64 and 98 nM for Cdk5 and Cdk2, respectively .

HY-101042

AG-494 Tyrphostin AG 494	EGFR CDK	Cancer
AG-494 (Tyrphostin AG 494) is a potent and selective EGFR tyrosine kinase inhibitor (IC₅₀=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC₅₀s 1.1, 39, 45 and 6 μM, respectively. AG-494 blocks Cdk2 activation and inhibits EGF-dependent DNA synthesis .

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent *CDK2* inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-114302

CCB02 1 Publications Verification	Microtubule/Tubulin	Cancer
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .

HY-112462

Cdk1/2 Inhibitor III	CDK	Cancer
Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective Cdk1/cyclin B and Cdk2/cyclin A inhibitor of with IC₅₀s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC₅₀ of 32 nM), GSK-3β (IC₅₀ of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC₅₀s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-170897

CDK2-IN-40	CDK	Cancer
CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits *CDK2*/Cyclin E1 with an IC₅₀ of ≤ 10 nM .

HY-148062

RSS0680	PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK	Others
RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, *CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase* activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].

HY-124321

Metralindole hydrochloride	CDK	Cancer
Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase *CDK2* and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .

HY-E70672

**CDK2/CycE1 Recombinant Human Active Protein Kinase**	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-112363

Aloisine A RP107	CDK GSK-3 ERK JNK CFTR	Inflammation/Immunology Cancer
Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC₅₀s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC₅₀=0.5 μM) and GSK-3β (IC₅₀=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research .

HY-147409

Ulecaciclib	CDK	Cancer
Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .

HY-W011428R

Olomoucine (Standard)	Reference Standards CDK	Others Cancer
Olomoucine is an ATP competitive inhibitor of CDKs. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both IC50=7 μM), CDK/p35 kinase (IC50=3 μM) and ERK1/p44 MAP kinase (IC50=25 μM) . Olomoucine regulates cell cycle and shows anti-melanin tumor activity .

HY-168057

PROTAC CDK2 Degrader-1	PROTACs CDK	Cancer
PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC₅₀ of 100-500 nM .

HY-E70674

**CDK2/CycO Recombinant Human Active Protein Kinase**	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .

HY-E70673

**CDK2/CycE2 Recombinant Human Active Protein Kinase**	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

HY-E70671

**CDK2/CycD1 Recombinant Human Active Protein Kinase**	CDK	Cancer
CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .

Cat. No.	Product Name	Target	Research Area

HY-P0235

CDK2	Peptides	Cancer
CDK2 is a member of the eukaryotic S/T protein kinase family and its function is to catalyze the phosphoryl transfer of ATP γ-phosphate to serine or threonine hydroxyl (denoted as S₀/T₀) in a protein substrate.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18981

Decursin 2 Publications Verification (+)-Decursin	Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Echinacea angustifolia DC. Source Classification	PKC Apoptosis CXCR
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent *protein kinase* C activator. Decursin induces apoptosis** and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

HY-N5072

Desmethylglycitein 3 Publications Verification 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Disease Research Fields Isoflavones Source Classification Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to *CDK1* and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-N5072R

Desmethylglycitein (Standard) 4',6,7-Trihydroxyisoflavone (Standard)	Structural Classification Flavonoids Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Isoflavones Source Classification	Reference Standards CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-18981R

Decursin (Standard) (+)-Decursin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Plants Echinacea angustifolia DC. Source Classification	Reference Standards PKC Apoptosis CXCR
Decursin (Standard) is the analytical standard of Decursin. This product is intended for research and analytical applications. Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities [4].

Species:	Human (9)
Tag:	His (10) Tag Free (1) Avi (1) GST (7) Flag (6)
Source:	HEK293 (1) sf9 insect cells (1) Sf9 insect cells (7) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70014

	CDK2 Protein, Human (His) rHuCyclin-dependent kinase 2/CDK2, His; Cyclin-Dependent kinase 2; Cell Division Protein kinase 2; p33 Protein kinase; CDK2; CDKN2	Human	E. coli
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2 Protein, Human (His) is the recombinant human-derived CDK2 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P705800

	CDK2 Protein, Human (sf9) rHuCyclin-dependent kinase 2/CDK2, His; Cyclin-Dependent kinase 2; Cell Division Protein kinase 2; p33 Protein kinase; CDK2; CDKN2	Human	sf9 insect cells

HY-P705801

	CDK2 Protein, Human (Biotinylated, His-Avi) rHuCyclin-dependent kinase 2/CDK2, His; Cyclin-Dependent kinase 2; Cell Division Protein kinase 2; p33 Protein kinase; CDK2; CDKN2	Human	E. coli

HY-P702675

	CDK2-CCNA2 Protein, Human (Active, sf9, GST, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCNA2 Protein, Human (sf9, GST, His) is the recombinant human-derived CDK2-CCNA2, expressed by Sf9 insect cells, with N-6*His, N-GST labeled tag.

HY-P702679

	CDK2-CCNO Protein, Human (Active, sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCNO Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK2-CCNO, expressed by Sf9 insect cells, with N-GST, N-Flag, N-His labeled tag.

HY-P702676

	CDK2-CCND1 Protein, Human (Active, sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK2-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P702677

	CDK2-CCNE1 Protein, Human (Active, sf9, GST, His, Flag) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCNE1 Protein, Human (sf9, GST, His, Flag) is the recombinant human-derived CDK2-CCNE1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P702678

	CDK2-CCNE2 Protein, Human (Active, sf9, GST, Flag, His) CDK2; cyclin-dependent kinase 2; p33 protein kinase; cell devision kinase 2; cdc2-related protein kinase; cell division protein kinase 2; p33(CDK2)	Human	Sf9 insect cells
	CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCNE2 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK2-CCNE2, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

HY-P703459

	CDK2/CCNE2 Protein, Sus scrofa (Active, sf9, GST, His, Flag) Cyclin-dependent kinase 2; Cell division protein kinase 2; CDK2; Sus scrofa; Pig; kinase; Serine/threonine-protein kinase; Transferase; 2.7.11.22	Others	Sf9 insect cells
	CDK2/CCNE2 Protein, Sus scrofa (sf9, GST, His, Flag) is the recombinant CDK2/CCNE2, expressed by sf9 insect cells , with His, GST, Flag labeled tag.

HY-P703475

	CDK2-CCNE1 Protein, Sus scrofa (Active, sf9, GST, His, Flag) Cyclin-dependent kinase 2; Cell division protein kinase 2; CDK2; Sus scrofa; Pig; kinase; Serine/threonine-protein kinase; Transferase; 2.7.11.22	Others	Sf9 insect cells

HY-P7850

	CDK2AP2 Protein, Human (HEK293, His) rHuCyclin-dependent kinase 2-associated protein 2/CDK2AP2, His; Cyclin-dependent kinase 2-associated protein 2; CDK2-associated protein 2; DOC-1-related protein; DOC-1R; CDK2AP2; DOC1R	Human	HEK293
	The CDK2AP2 protein is an important component of the NuRD complex and actively participates in chromatin remodeling. It inhibits the G1/S phase transition by inhibiting CDK2 and preventing the interaction of CDK2 with cyclin E or A. CDK2AP2 Protein, Human (HEK293, His) is the recombinant human-derived CDK2AP2 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-18981S

Decursin-d6

Decursin-d₆ ((+)-Decursin-d₆) is the deuterium labeled Decursin (HY-18981). Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .

Host:	Mouse (1) Rabbit (9)
Reactivity:	Human (9) Rat (9) Mouse (7) Hamster (2)
Application:	IHC-P (5) ICC/IF (5) IF-Tissue (1) IP (5) WB (10) FC (2) Dot Blot (1) ELISA (1)
Isotype:	IgG (9) IgG1 (1)
Conjugation:	Non-conjugated (10) Biotin (1)
Clonality:	Monoclonal (6) Recombinant (4)
Modification:	Phosphorylated (1) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86535

	CDK2 Antibody (YA6227) CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	CDK2 Antibody (YA6227) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK2.

HY-P80076

	CDK2 Antibody (YA514) 1 Publications Verification Cdc2 related protein kinase; CDC28; CDC2A; CDK 2; CDK1; CDK2; CDK2_HUMAN ; CDKN2; MPF; p33(CDK2) antibody;	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse, Rat
	CDK2 Antibody (YA514) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDK2.

HY-P80798

	Phospho-CDK2 (Tyr15) Antibody (YA217) 1 Publications Verification CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase	WB, IP	Human, Hamster, Rat
	Phospho-CDK2 (Tyr15) Antibody (YA217) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CDK2 (Tyr15).

HY-P810606

	Phospho-Cdk2 (Tyr15) Antibody (YA9868) CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase	WB, IHC-P, IP, IF-Tissue	Human, Mouse, Rat
	Phospho-Cdk2 (Tyr15) Antibody (YA9868) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-Cdk2 (Tyr15).

HY-P80798A

	Phospho-CDK2 (Tyr15) Antibody (YA217)(PBS only) CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase	WB, IP	Human, Hamster, Rat
	Phospho-CDK2 (Tyr15) Antibody (YA217) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CDK2 (Tyr15).

HY-P810605

	Phospho-CDK1 (Thr161) + CDK2/CDK3 (Thr160) Antibody (YA9867) CDK2; CDKN2; Cyclin-dependent kinase 2; Cell division protein kinase 2; p33 protein kinase	WB, Dot Blot	Human
	Phospho-CDK1 (Thr161) + CDK2/CDK3 (Thr160) Antibody (YA9867) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-CDK1 (Thr161) + CDK2/CDK3 (Thr160).

HY-P81587

	SKP2 Antibody (YA1332) SKP2; FBXL1; S-phase kinase-associated protein 2; Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	SKP2 Antibody (YA1332) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SKP2.

HY-P85367

	SKP2 Antibody (YA5059) SKP2; FBXL1; S-phase kinase-associated protein 2; Cyclin-A/CDK2-associated protein p45; F-box protein Skp2; F-box/LRR-repeat protein 1; p45skp2	WB, IHC-P	Mouse, Rat
	SKP2 Antibody (YA5059) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to SKP2.

HY-P82229

	SKP1 Antibody (YA1974) SKP1; EMC19; OCP2; SKP1A; TCEB1L; S-phase kinase-associated protein 1; Cyclin-A/CDK2-associated protein p19; Organ of Corti protein 2; OCP-2; Organ of Corti protein II; OCP-II; RNA polymerase II elongation factor-like protein; SIII; Transcr	WB, ICC/IF	Human, Mouse, Rat
	SKP1 Antibody (YA1974) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SKP1.

HY-P82229A

	SKP1 Antibody (YA1974)(PBS only) SKP1; EMC19; OCP2; SKP1A; TCEB1L; S-phase kinase-associated protein 1; Cyclin-A/CDK2-associated protein p19; Organ of Corti protein 2; OCP-2; Organ of Corti protein II; OCP-II; RNA polymerase II elongation factor-like protein; SIII; Transcr	WB, ICC/IF	Human, Mouse, Rat
	SKP1 Antibody (YA1974) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SKP1.